The Zhitong Finance App learned that on Wednesday, Genmab (GMAB.US) opened high. As of press release, the increase was nearly 26%, and the increase in October was over 58%. According to the news, Genmab announced the latest data from its Petosemtamab phase III Liger-HN1 study, showing that combined treatment with this therapy can reduce the risk of death in patients with head and neck squamous cell carcinoma by 50%. Genmab said a phase 3 clinical trial of petosemtamab combined with pabolizumab reached two major endpoints. The study evaluated this combined protocol in first-line patients with PD-L1-positive, recurrent, or metastatic squamous cell carcinoma of the head and neck. The company added that the combined program reduced the risk of death by 50% compared to pabolizumab alone.

The Zhitong Finance App learned that on Wednesday, Genmab (GMAB.US) opened high. As of press release, the increase was nearly 26%, and the increase in October was over 58%. According to the news, Genmab announced the latest data from its Petosemtamab phase III Liger-HN1 study, showing that combined treatment with this therapy can reduce the risk of death in patients with head and neck squamous cell carcinoma by 50%. Genmab said a phase 3 clinical trial of petosemtamab combined with pabolizumab reached two major endpoints. The study evaluated this combined protocol in first-line patients with PD-L1-positive, recurrent, or metastatic squamous cell carcinoma of the head and neck. The company added that the combined program reduced the risk of death by 50% compared to pabolizumab alone.